Breaks Categories: News

MondayMay 10, 2021 10:11 am

NetworkNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Enters Master Agreement with Leading CRO Clinlogix

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, has entered into a master service agreement with Clinlogix, a contract research organization (“CRO”). The agreement is a key step for initiating and supporting the clinical development of Tryp’s psilocybin-for-neuropsychiatric disorders, or PFN(TM) (“PFN”), program. Tryp noted that Clinlogix has global experience in providing CRO services for the development of novel pharmaceutical products, and the agreement outlines the collaboration between the two companies, as well as other clinical partners, will include medical writing, biostatistical analysis, data management and trial monitoring. The…

Continue Reading

MondayMay 10, 2021 9:34 am

NetworkNewsBreaks – BAND Royalty Announces Completion of New Music Presale Totaling $1M in NFTs

BAND Royalty, an entertainment and technology-driven firm and a leading innovator of music-focused NFTs operated by Singapore-based Liberty IS PTE LTD (“Liberty IS PTE LTD”), has announced the completion of the private presale round of its NFT music art BAND NFT Series 1 collectibles. The presale round included a small group of NFT collectors who love music. The announced noted that the top three BAND NFT albums, called Diamond albums, were purchased for 60 ETH (“ETH”) in total, which is the equivalent of more than $200,000. BAND Royalty observed that NFT collectors were eager to participate in the presale and…

Continue Reading

FridayMay 07, 2021 1:40 pm

NetworkNewsBreaks – DGTL Holdings Inc. (TSX.V: DGTL) (OTCQB: DGTHF) Strong Presence as Savvy Companies Seek Martech Options

DGTL Holdings (TSX.V: DGTL) (OTCQB: DGTHF) is the focus of a recent NetworkNewsAudio news podcast. The podcast talked about the impact COVID-19 has had on martech and digital advertising. The piece points out that in today’s world, savvy brands realize that they must transition to digital outreach or fail. The podcast cites a recent survey that reported more than 49% respondents said they shop more online now than pre-COVID, including 62% of Americans, 59% in Canada and 70% in Mexico. Another study indicated that 70% of businesses surveyed said that marketing had become more important during the pandemic for reasons spanning…

Continue Reading

FridayMay 07, 2021 1:28 pm

NetworkNewsBreaks – Infobird Co. Ltd. (NASDAQ: IFBD) Featured in Exclusive Broadcast

Infobird (NASDAQ: IFBD)  today announced the availability of a broadcast titled, “China Is Next Frontier in SaaS Revolution.” The piece discusses Infobird’s positioning as one of the few software-as-a-service (“SaaS”) companies in China with the capability to transition into a standard SaaS business model and serve both mid-to-large enterprises and SMEs by leveraging its no-code development platform. According to the audio press release, “A leading SaaS provider of patented, innovative AI-powered, customer-engagement solutions in China, the company earned its stripes by creating and delivering customized SaaS solutions for some of the largest commercial banks in the nation. Coming off a…

Continue Reading

FridayMay 07, 2021 1:04 pm

NetworkNewsBreaks – Amesite Inc. (NASDAQ: AMST) Founder, CEO Featured Guest on RedChip Money Report Interview

Amesite (NASDAQ: AMST), an artificial intelligence software company providing offering a cloud-based platform and content creation services for business, university and K-12 learning and upskilling, has announced that founder and CEO Dr. Ann Marie Sastry will be the featured guest speaker on a recent interview to be broadcast on “The RedChip Money Report(R),” which offers commentary on small-cap investing as well as interview with executives of public companies. The  interview is scheduled for broadcast on Bloomberg TV on Saturday, May 8, 2021, at 7 p.m. local times; the broadcast will reach 73 million homes in the United States. In addition, the interview is available…

Continue Reading

FridayMay 07, 2021 12:57 pm

NetworkNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Host Conference/Webcast to Discuss Q1 Results, Provide Clinical Pipeline Update

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, today announced that it will host a conference call and live webcast to discuss its first quarter 2021 results and provide an update on its clinical pipeline. The event is scheduled to take place at 5:30 p.m. ET on Thursday, May 13, 2021. Interested parties may visit https://nnw.fm/rMRlW to register, as well as join the call by dialing 888-506-0062 (Toll-Free) or 973-528-0016 (International) and entering code: 396394. Participants are asked to dial in approximately five…

Continue Reading

FridayMay 07, 2021 12:09 pm

NetworkNewsBreaks – Karuna Therapeutics, Inc. (NASDAQ: KRTX) Featured in Mizuho Securities Research Report

Karuna Therapeutics (NASDAQ: KRTX) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “Karuna released 1Q21 earnings today, but quarterly financial performance is less important for a clinical-stage company such as Karuna. More important are updates on the progress of flagship drug KarXT, and we are encouraged by the progress there. The two pivotal Phase 3 trials (EMERGENT-2 and EMERGENT-3) and 52-week EMERGENT-4 trial are enrolling, while EMERGENT-5 will be initiated in 2Q21. The Phase 1b safety and tolerability trial in healthy elderly volunteers also continues, with Cohort 3 data expected later…

Continue Reading

FridayMay 07, 2021 12:08 pm

NetworkNewsBreaks – Nkarta, Inc. (NASDAQ: NKTX) Featured in Mizuho Securities Research Report

Nkarta (NASDAQ: NKTX) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “Nkarta and CRISPR Therapeutics (CRSP, not covered) announced a 50/50 collaboration to develop two NK cell therapies. One of these will target CD70 for indications including solid tumors and one is still TBD. They will also develop a combination NK+T cell therapy to target both innate and adaptive immunity. Additionally, Nkarta receives a license to use CRISPR technology to edit five gene targets in any of its own assets.”To request access to the full report, visit http://nnw.fm/SaZ9d About Nkarta, Inc.Nkarta is…

Continue Reading

FridayMay 07, 2021 12:06 pm

NetworkNewsBreaks – Assembly Biosciences Inc. (NASDAQ: ASMB) Featured in Mizuho Securities Research Report

Assembly Biosciences (NASDAQ: ASMB) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “Assembly released its 1Q21 results after the bell, and we had a chance to catch up with management this evening. The new information is incremental in nature in that we're getting some in-the-weeds data at EASL. It likely won't change the overall picture of the ASMB story or answer the finite therapy question, but it's something to look forward to for anybody deep in HBV in what has mostly been a quiet first half for the stock. FWIW --…

Continue Reading

FridayMay 07, 2021 12:05 pm

NetworkNewsBreaks – Coherus BioSciences Inc. (NASDAQ: CHRS) Featured in Mizuho Securities Research Report

Coherus BioSciences (NASDAQ: CHRS) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “Udenyca's alternative dosing formulations and tori clinical programs, among other topics, were discussed. Key tidbits below: Udenyca. Net Udenyca sales were $83MM in 1Q21 compared to $110MM in 4Q20, a ~25% qoq decrease that according to management was a result of: 1) Inventory changes (inventory business days are as follows: end of 3Q20 11 business days, end of 4Q20 21 business days, end of 1Q21 12 business days), and by our math, each business day is worth $1.5MM; and…

Continue Reading